Statin therapy and aortic stenosis: A systematic review of the effects of statin therapy on aortic stenosis

American Journal of Therapeutics

Volumn 17, Issue 4, 2010, Pages

  Loomba, Rohit Seth ^a   Arora, Rohit ^b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

aortic valve; statin; stenosis

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; HYPOCHOLESTEROLEMIC AGENT;

AORTA STENOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CANCER INCIDENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; HEART HEMODYNAMICS; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; AORTIC VALVE STENOSIS; CALCINOSIS; DRUG EFFECTS; HEMODYNAMICS; NEOPLASMS; OSSIFICATION, HETEROTOPIC; PATHOPHYSIOLOGY;

ANTICHOLESTEREMIC AGENTS; AORTIC VALVE STENOSIS; CALCINOSIS; DISEASE PROGRESSION; HEMODYNAMICS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NEOPLASMS; OSSIFICATION, HETEROTOPIC;

EID: 77954965610     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181a2b1a6     Document Type: Review

References (25)

1. Stewart BF, Siscovik D, Lind BK, et al. Clincal factors associated with calcific aortic valve disease. J Am Coll Cardiol. 1997;29:630-634.
2. Novaro GM, Katz R, Aviles RJ, et al. Clinical factors but not C reactive protein, predict progression of calcific aortic valve disease. J Am Coll Cardiol. 2007;50:1992-1998.
3. Brener SJ, Duffy CI, Thomas JD, et al. Progression of aortic stenosis in 394 patients: relation to changes in myocardial and mitral valve dysfunction. J Am Coll Cardiol. 1995;25: 305-310.
4. Mohler ER, Sheridan MJ, Nichols R, et al. Development and progression of aortic valve stenosis: atherosclerosis risk factor-a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995-999.
5. Otto CM, Kuusisto J, Reichebach DD, et al. Characterizatin of the early lesion of degenerative valvular aortic stenosis. Circulation. 1994;90:844-853.
6. Clark RE, Finke ED. Scanning and light microscopy of human aortic leaflets in stressed and relaxed states. J Thorac Cardiovasc Surg. 1974;67:792-804.
7. Thubrikar MJ, Nolan SP, Aouad J, et al. Stress sharing between the sinus and leaflets of canine aortic valve. Ann Thoracic Surg. 1986;20:434-440.
8. Beppu S, Suzuki S, Matsuda H, et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol. 1993;71:322-327.
9. Lindroos M, Kupari M, Valvanne J, et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15:865-870.
10. Wallby L, Janerot-Sjoberg B, Steffensen T, et al. T lymphocyte infiltration in non-rheumatic aortic stenosis: a comparative descriptive study between tricuspid and bicuspid aortic valves. Heart. 2002;88:348-351.
11. Fox CS, Guo C, Larson M, et al. Relations of inflammation and novel risk factors to valvular calcification. Am J Cardiol. 2005;97:1502-1505.
12. Inoue I, Goto S, Mizotani K, et al. Lipophilic HmgCoA reductase inhibitor has an anti-inflammatory effect. Life Sci. 2000;67:863-876.
13. Laufs U, La Fata V, Liao JK. Inhibition of HMG CoA reductase blocks hypoxia mediated down regulation of endothelial nitric oxide synthase. J Biol Chem. 1997;272: 31725-31729.
14. Romano M, Diomede L, Sironi M, et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest. 2000;80:1095-1100.
15. Ortego M. Atorvastatin reduces NF-kappB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
16. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071.
17. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, A, and E accumulate in the morphologically early lesion of degenerative valvular aortic stenosis. Aterioscler Thromb Vasc Biol. 1996;16:523-532.
18. Mohler ER 3rd, Gannon F, Reynold C, et al. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522-1528.
19. Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184.
20. Watson KE, Bostrom K, Ravindranath R. TGF-beta 1 and 25- hydroxycholesterol stimulate osteoblast-like vascular cell to calcify. J Clinic Invest. 1994;93:2106-12013
21. O'Brien KD, Kuusisto J, Reichenbach DD, et al. Osteopontin is expressed in human aortic valvular lesions. Circulation. 1995;92:2163-2168.
22. Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378-387.
23. Jukema JW. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation. 1995;91:2528-2540.
24. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
25. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.